ChiCTR2300072455 版本V1.0 版本创建时间2023/06/14 11:26:55 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300072455 

最近更新日期:

Date of Last Refreshed on:

2023-06-14 11:26:31 

注册时间:

Date of Registration:

2023-06-14 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

右美托咪定联合艾司氯胺酮对腹腔镜手术患者术后PONV的影响

Public title:

Combination of dexmedetomidine and Esketamine for postoperative nausea and vomiting in patients undergoing laparoscopic surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

右美托咪定联合艾司氯胺酮对腹腔镜手术患者术后PONV的影响

Scientific title:

Combination of dexmedetomidine and Esketamine for postoperative nausea and vomiting in patients undergoing laparoscopic surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张超 

研究负责人:

张超 

Applicant:

Chao Zhang 

Study leader:

Chao Zhang 

申请注册联系人电话:

Applicant telephone:

+86 188 6256 8088

研究负责人电话:

Study leader's telephone:

+86 188 6256 8088

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ztony1345@gmail.com

研究负责人电子邮件:

Study leader's E-mail:

ztony1345@gmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

https://www.szsdjrmyy.com/

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国江苏省苏州市吴江区芦荡路2666号

研究负责人通讯地址:

中国江苏省苏州市吴江区芦荡路2666号

Applicant address:

No. 2666 Ludang Road, Wujiang District, Suzhou City, Jiangsu Province, China

Study leader's address:

No. 2666 Ludang Road, Wujiang District, Suzhou City, Jiangsu Province, China

申请注册联系人邮政编码:

Applicant postcode:

215200

研究负责人邮政编码:

Study leader's postcode:

215200

申请人所在单位:

苏州大学附属苏州九院

Applicant's institution:

Suzhou Ninth Hospital Affiliated to Soochow University

研究负责人所在单位:

苏州大学附属苏州九院

Affiliation of the Leader:

Suzhou Ninth Hospital Affiliated to Soochow University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023067

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

苏州市第九人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Suzhou Ninth People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-05-01 00:00:00

伦理委员会联系人:

袁莺

Contact Name of the ethic committee:

Ying Yuan

伦理委员会联系地址:

中国江苏省苏州市吴江区太湖新城芦荡路2666号

Contact Address of the ethic committee:

No. 2666 Ludang Road, Taihu New Town, Wujiang District, Suzhou City, Jiangsu Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 512 8288 1374

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

苏州大学附属苏州九院

Primary sponsor:

Suzhou Ninth Hospital Affiliated to Soochow University

研究实施负责(组长)单位地址:

中国江苏省苏州市吴江区芦荡路2666号

Primary sponsor's address:

No. 2666 Ludang Road, Wujiang District, Suzhou City, Jiangsu Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

苏州

Country:

China

Province:

Jiangsu

City:

Suzhou

单位(医院):

苏州大学附属苏州九院

具体地址:

中国江苏省苏州市吴江区芦荡路2666号

Institution
hospital:

Suzhou Ninth Hospital Affiliated to Soochow University

Address:

No. 2666 Ludang Road, Wujiang District, Suzhou City, Jiangsu Province, China

经费或物资来源:

自筹项目

Source(s) of funding:

self-funded project

Target disease:

postoperative nausea and vomiting

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

阐明联合使用右美托咪定和艾氯胺酮对腹腔镜手术患者术后恶心呕吐的预防效果。  

Objectives of Study:

Elucidate the prophylactic effect of combining dexmedetomidine and S-ketamine on postoperative nausea and vomiting in laparoscopic surgery patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄18~65岁 2.ASA分级Ⅰ~Ⅱ级 3.体重指数在18-30kg/m^2 4.计划进行腹腔镜手术的患者

Inclusion criteria

1. Age18~65 years. 2. American Society of Anesthesiologists (ASA) physical status I–III. 3. Body mass index (BMI) 18–30kg/m^2. 4. Scheduled for laparoscopic surgery.

排除标准:

1.窦性病变综合征或严重的心动过缓(心率 <50次/分钟)。 2.有高血压或心脏功能不全的病史。 3.Ⅱ度或Ⅱ度以上的房室传导阻滞且没有安装起搏器。 4.左室射血分数 <40%。 5.有冠心病或心肌梗死病史。 6.肝功能或肾功能异常(Child-Pugh分级C或接受肾脏替代治疗)。 7.帕金森病或阿尔茨海默病。 8.癫痫或癫痫持续状态。 9.妊娠或哺乳期。 10.慢性疼痛的病史或术前使用镇静剂或镇痛剂。 11.对本研究中的药物过敏。

Exclusion criteria:

1. Sick sinus syndrome or severe bradycardia (heart rate (HR) <50 beats/min). 2. History of hypertension or cardiac insufficiency 3. Second-degree or greater atriocentric block without a pacemaker. 4. Left ventricular ejection fraction <40%. 5. Coronary heart disease or history of myocardial infarction. 6. Liver or renal dysfunction (Child-Pugh class C or undergoing renal replacement therapy). 7. Parkinson's disease or Alzheimer's disease. 8. Seizures or epilepsy. 9. Pregnancy or breast feeding. 10. History of chronic pain or preoperative use of sedatives or analgesics. 11. Allergies to medications in this study.

研究实施时间:

Study execute time:

From 2023-06-15 00:00:00 To 2023-11-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-06-15 00:00:00 To 2023-11-01 00:00:00  

干预措施:

Interventions:

组别:

联合用药组

样本量:

70

Group:

Combination therapy group

Sample size:

干预措施:

联合用药组采用静脉注射右美托咪定 0.5μg/kg (注射时间大于10 分钟),艾司氯胺酮 0.3mg/kg ,舒芬太尼0.2ug/kg和异丙酚 1.5–2.0mg/kg进行麻醉诱导; 术中采用吸入 2%–3% 七氟烷维持麻醉。

干预措施代码:

Intervention:

The combined therapy group underwent anesthesia induction with intravenous administration of dexmedetomidine at a dosage of 0.5 μg/kg (injected over a period exceeding 10 minutes), s-ketamine at a dosage of 0.3 mg/kg, sufentanil at a dosage of 0.2 μg/kg, and propofol at a dosage of 1.5-2.0 mg/kg. During the surgery, maintenance of anesthesia was achieved with inhalation of 2%-3% sevoflurane.

Intervention code:

组别:

对照组

样本量:

70

Group:

Control group

Sample size:

干预措施:

对照组采用静脉注射舒芬太尼0.5ug/kg和异丙酚 1.5–2.0mg/kg进行麻醉诱导; 术中采用吸入 2%–3% 七氟烷和静脉泵注瑞芬太尼0.1μg/kg/min维持麻醉。

干预措施代码:

Intervention:

For the control group, anesthesia induction was achieved via intravenous administration of sufentanil at a dosage of 0.5 μg/kg and propofol at a dosage of 1.5-2.0 mg/kg. During the surgical procedure, maintenance of anesthesia was accomplished by inhalation of 2%-3% sevoflurane and continuous infusion of remifentanil at a rate of 0.1 μg/kg/min via intravenous pump.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

苏州 

Country:

China 

Province:

Jiangsu 

City:

Suzhou 

单位(医院):

苏州大学附属苏州九院 

单位级别:

三乙 

Institution
hospital:

Suzhou Ninth Hospital Affiliated to Soochow University

Level of the institution:

Tertiary B

测量指标:

Outcomes:

指标中文名:

心率

指标类型:

主要指标

Outcome:

heart rate

Type:

Primary indicator

测量时间点:

整个围手术期

测量方法:

Measure time point of outcome:

throughout the perioperative period

Measure method:

指标中文名:

血压

指标类型:

主要指标

Outcome:

blood pressure

Type:

Primary indicator

测量时间点:

整个围手术期

测量方法:

Measure time point of outcome:

throughout the perioperative period

Measure method:

指标中文名:

PONV发生率

指标类型:

主要指标

Outcome:

incidence of post-operative nausea and vomiting

Type:

Primary indicator

测量时间点:

术后48小时内

测量方法:

Measure time point of outcome:

within 48 hours after operation

Measure method:

指标中文名:

恶心

指标类型:

主要指标

Outcome:

nausea

Type:

Primary indicator

测量时间点:

术后48小时内

测量方法:

Measure time point of outcome:

within 48 hours after operation

Measure method:

指标中文名:

呕吐

指标类型:

主要指标

Outcome:

vomiting

Type:

Primary indicator

测量时间点:

术后48小时内

测量方法:

Measure time point of outcome:

within 48 hours after operation

Measure method:

指标中文名:

噩梦

指标类型:

副作用指标

Outcome:

nightmare

Type:

Adverse events

测量时间点:

术后48小时内

测量方法:

Measure time point of outcome:

within 48 hours after operation

Measure method:

指标中文名:

嗜睡

指标类型:

副作用指标

Outcome:

drowsiness

Type:

Adverse events

测量时间点:

术后48小时内

测量方法:

Measure time point of outcome:

within 48 hours after operation

Measure method:

指标中文名:

心动过缓

指标类型:

副作用指标

Outcome:

bradycardia

Type:

Adverse events

测量时间点:

术中与PACU中

测量方法:

Measure time point of outcome:

Intraoperative and PACU time

Measure method:

指标中文名:

抗呕吐治疗

指标类型:

次要指标

Outcome:

anti-emetic treatment

Type:

Secondary indicator

测量时间点:

术后48小时内

测量方法:

Measure time point of outcome:

within 48 hours after operation

Measure method:

指标中文名:

术后镇痛补救

指标类型:

次要指标

Outcome:

postoperative analgesia rescue

Type:

Secondary indicator

测量时间点:

术后48小时内

测量方法:

Measure time point of outcome:

within 48 hours after operation

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

通过随机数字表产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Generate a random sequence through a random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

由于麻醉技术之间的差异,麻醉实施者不能对分组设盲;但是麻醉实施者不会参与患者招募、数据收集或统计学分析。外科医师、术后医护人员以及负责结果评估及统计学分析的人员将对分组不知情。

Blinding:

Due to disparities in anesthesia techniques, it is not feasible to implement blinding of the treatment groups among anesthesia providers. Nevertheless, it should be noted that anesthesia providers will not participate in patient recruitment, data collection, or statistical analysis. Surgeons, postoperative medical staff, and individuals responsible for outcome evaluation and statistical analysis will be kept unaware of the group allocations.

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

与通讯作者联系获取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The original data can be obtained with the approval from the corresponding author.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

纸质资料及电子资料保存在苏州大学附属苏州九院

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Paper materials and electronic materials are kept in Suzhou Ninth Hospital Affiliated to Soochow University.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-06-14 11:26:31